

**AMENDMENT #2 TO MASTER CLINICAL STUDY AGREEMENT**

This AMENDMENT #2 is entered into this 18th day of September, 2006, and amends the Master Clinical Study Agreement entered into by SmithKline Beecham Corporation, doing business as GlaxoSmithKline ("GSK") and one of the following component institutions ("Institution" and collectively "Institutions") of The University of Texas System ("System") located at 201 West 7th Street, Austin, Texas 78701, that is governed by its Board of Regents ("Board") as named in Exhibit B: The University of Texas Health Center at Tyler, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at San Antonio, The University of Texas M.D. Anderson Cancer Center, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center at Dallas, which was effective the 10th day of November, 2003 ("Master Agreement"). The Master Agreement was first amended April 6, 2005 (Amendment #1).

Pursuant to the terms of the Master Agreement allowing for modification of the same, the parties hereby agree to **add** new Section 10(f), Indemnification, of the Master Agreement in its entirety as follows:

**10. INDEMNIFICATION**

...

(f) For the Study performed under this Agreement, GSK will offer Study patients compensation for Study-related injuries, through the Study's informed consent process. If Institution provides a Study patient medical care for which compensation is available from GSK under the terms of the informed consent for the Study, GSK agrees to pay Institution directly on the Study patient's behalf for the care provided.

If any provision of this Amendment #2 is inconsistent with the terms of the Master Agreement, the terms of this Amendment #2 shall prevail. Other than the modifications provided herein, the remaining terms of the Master Agreement and Amendment #1 remain in full force and effect.

**IN WITNESS WHEREOF**, the parties have acknowledged their consent to this Amendment #2 by executing it as of the day and year above written.

**SMITHKLINE BEECHAM  
CORPORATION  
d/b/a GLAXOSMITHKLINE**

By: Craig Wozniak  
Craig Wozniak  
Vice President, North America  
Regional Clinical Operations

Date: 18 September 2006

**THE UNIVERSITY OF TEXAS HEALTH  
CENTER AT TYLER**

By: Vernon Moore

Name: Vernon Moore  
Title: Chief Business and Finance Officer

Date: 11/2/06

**THE UNIVERSITY OF TEXAS HEALTH  
SCIENCE CENTER AT HOUSTON**

By: *Johnna K. Kincaid*

Name: Johnna K. Kincaid

Title: Executive Director, Sponsored Proj Admin

Date: 10/17/06

**THE UNIVERSITY OF TEXAS HEALTH  
SCIENCE CENTER AT SAN ANTONIO**

By: *Jane Youngers*

Name: Jane Youngers

Title: Assistant VP for Research & Sponsored Projects

Date: 10-12-06

~~**THE UNIVERSITY OF TEXAS M. D. <sup>NW</sup>  
ANDERSON CANCER CENTER**~~

~~By: \_\_\_\_\_~~

~~Name: \_\_\_\_\_~~

~~Title: \_\_\_\_\_~~

~~Date: \_\_\_\_\_~~

**THE UNIVERSITY OF TEXAS MEDICAL  
BRANCH AT GALVESTON**


By: *Susan E. Ramsey*

Name: Susan Ramsey

Title: Manager of Research Operations

Date: 10/25/06

**THE UNIVERSITY OF TEXAS  
SOUTHWESTERN MEDICAL CENTER  
AT DALLAS**

By:  \_\_\_\_\_

Name: Perrie M. Adams, Ph.D.

Title: Associate Dean for Research

Date: 10/27/06